

Supplemental Table 1. Select baseline demographic and disease characteristics for DISCOVER-2 patients.

	Guselkumab Q4W	Guselkumab Q8W	Placebo
Patients, N	245	248	246
Age, years	45.9 ± 11.5	44.9 ± 11.9	46.3 ± 11.7
Female	103 (42)	119 (48)	129 (52)
PsA disease duration, years	5.5 ± 5.9	5.1 ± 5.5	5.8 ± 5.6
Tender joint count (0-68)	22.4 ± 13.5	19.8 ± 11.9	21.6 ± 13.1
Swollen joint count (0-66)	12.9 ± 7.8	11.7 ± 6.8	12.3 ± 6.9
PtGA (arthritis; VAS 0-10)	6.4 ± 1.9	6.5 ± 1.9	6.5 ± 1.8
HAQ-DI (0-3)	1.2 ± 0.6	1.3 ± 0.6	1.3 ± 0.6
PASDAS	6.6 ± 1.1	6.6 ± 1.1	6.6 ± 0.9
DAPSA	49.7 ± 21.1	46.3 ± 19.4	48.8 ± 19.4
Patients with enthesitis	170 (69)	158 (64)	178 (72)
Patients with dactylitis	121 (49)	111 (45)	99 (40)

Data reported as mean ± (standard deviation) or n (%) unless otherwise noted.

DAPSA, Disease Activity in Psoriatic Arthritis; HAQ-DI, Health Assessment Questionnaire-Disability Index;

PASDAS, Psoriatic Arthritis Disease Activity Score; PtGA, patient's global assessment; Q4W, every 4 weeks;

Q8W, every 8 weeks

Supplemental Table 2. Observed mean changes in PsA-modified vdH-S scores through Week 52 in DISCOVER-2 patients evaluated in reading session 2*

	Guselkumab Q4W		Guselkumab Q8W		Placebo (W0-24) → Guselkumab Q4W (W24-52)	
	W0-24 N=232	W24-52 N=229	W0-24 N=238	W24-52 N=235	W0-24 N=231	W24-52 N=230
Change in PsA-modified vdH-S score						
Total	0.5 (2.5)	0.6 (2.5)	0.7 (2.5)	0.2 (1.8)	1.0 (3.2)	0.2 (1.6)
Erosion	0.3 (1.9)	0.4 (1.7)	0.6 (2.0)	0.1 (1.4)	0.8 (2.3)	0.2 (1.3)
Joint space narrowing	0.2 (1.0)	0.2 (1.1)	0.2 (0.8)	0.1 (0.7)	0.2 (1.1)	0.1 (0.6)

Data presented as mean (standard deviation).

PsA-modified vdH-S score, van der Heijde-Sharp score modified for psoriatic arthritis; Q4W, every 4 weeks; Q8W, every 8 weeks; W, week

*Reading session 2 included patients continuing study treatment at Week 24 with images at Weeks 0, 24, and 52 (or at discontinuation after Week 24).